CA2796884A1 — Improved controlled release oral dosage form
Assigned to Andrx Pharmaceuticals LLC · Expires 2002-08-15 · 24y expired
What this patent protects
A pharmaceutical composition designed for once daily dosing of bupropion comprising: (A) a sustained release form of bupropion comprising: (i) a core comprising bupropion or a pharmaceutically acceptable salt or stereoisomer thereof, and (ii) a sustained release component, and (B…
USPTO Abstract
A pharmaceutical composition designed for once daily dosing of bupropion comprising: (A) a sustained release form of bupropion comprising: (i) a core comprising bupropion or a pharmaceutically acceptable salt or stereoisomer thereof, and (ii) a sustained release component, and (B) an immediate release form of bupropion or a pharmaceutically acceptable salt or stereoisomer thereof.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.